<DOC>
	<DOC>NCT00909584</DOC>
	<brief_summary>This is a multicenter Phase 2 randomized parallel-group study to determine the effect of Telintra treatment on severe chronic neutropenia. Patients will be randomized to Telintra or enter an observation period with an option to crossover to Telintra treatment in a 1:1 allocation.</brief_summary>
	<brief_title>Study of Ezatiostat (Telintra Tablets) for Treatment of Severe Chronic Neutropenia</brief_title>
	<detailed_description />
	<mesh_term>Neutropenia</mesh_term>
	<criteria>Confirmed Idiopathic Severe Chronic Neutropenia ECOG performance status of 02 Adequate liver and renal function Adequate Red Blood Cell and Platelet counts Prior treatment of SCN NonIdiopathic types of SCN, ie. cyclic, congenital History of chromosomal abnormalities, myelodysplasia, hematologic malignancy, aplastic anemia, systemic lupus erythematosus, rheumatoid arthritis (Felty's syndrome), or other collagen diseases, and druginduced neutropenia, autoimmune neutropenia Use of granulocyte colony stimulating factors (GCSF), glucocorticoids, gamma globulin, lithium or investigational drug(s) within one month of enrollment History of bone marrow transplantation or stem cell support</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Hematology</keyword>
	<keyword>Neutropenia</keyword>
	<keyword>SCN</keyword>
	<keyword>Severe Chronic Neutropenia</keyword>
	<keyword>Idiopathic</keyword>
	<keyword>Telintra</keyword>
	<keyword>ezatiostat hydrochloride</keyword>
	<keyword>ezatiostat</keyword>
	<keyword>TLK199</keyword>
	<keyword>Glutathione</keyword>
	<keyword>Glutathione analog</keyword>
	<keyword>Glutathione Transferase</keyword>
	<keyword>Glutathione Transferase inhibitor</keyword>
	<keyword>Glutathione Transferase P1-1 inhibitor</keyword>
	<keyword>GSTp1-1 inhibitor</keyword>
	<keyword>Apoptosis</keyword>
	<keyword>Differentiation</keyword>
	<keyword>Enzyme inhibitor</keyword>
</DOC>